A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Berberine may be new social media influencers, but this compound been a part of Chinese and Ayurvedic medicine practices for ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo.

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...